Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria~1. Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation~2. Age 18 years or older~3. Patients with severe hypertension as defined SBP greater than 180 mmHg and DBP greater than 95 mmHg at randomisation~4. Ability to stop any current antihypertensive therapy without unacceptable risk to the patient (Investigators discretion)~Exclusion criteria Mean in-clinic seated cuff SBP \>/= 200 mmHg and/or Diastolic Blood Pressure \[DBP\] \>/= 95 mmHg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- telmisartan and amlodipine (Type: EXPERIMENTAL): telmisartan and amlodipine used in combination vs amlodipine or telmisartan
- amlodipine (Type: ACTIVE_COMPARATOR): telmisartan and amlodipine used in combination vs amlodipine or telmisartan
- telmisartan (Type: ACTIVE_COMPARATOR): telmisartan and amlodipine used in combination vs amlodipine or telmisartan

Based on this trial design, predict the completion outcome and termination type (if applicable).